Halozyme Therapeutics, Inc. (HALO)
68.52
-0.46
(-0.67%)
USD |
NASDAQ |
May 21, 16:00
68.52
0.00 (0.00%)
After-Hours: 19:59
Halozyme Therapeutics EPS Diluted (Quarterly) : 1.221 for March 31, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 4.024 |
| Agenus, Inc. | 1.023 |
| Inovio Pharmaceuticals, Inc. | -0.2848 |
| Curis, Inc. | -1.250 |
| LadRx Corp. | -1.453 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | 150.05M |
| Revenue (Quarterly) | 376.71M |
| Total Expenses (Quarterly) | 226.66M |
| Enterprise Value | 9.953B |
| Gross Profit Margin (Quarterly) | 71.13% |
| Profit Margin (Quarterly) | 39.83% |
| Earnings Yield | 4.06% |
| Operating Earnings Yield | 10.30% |
| Normalized Earnings Yield | 7.120 |